Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Inclusion Criteria: 1. Provision of written Informed Consent Form (ICF) prior to any study specific procedures; 2. Male and Female aged between 18 and 75 years are eligible; 3. Histologically or cytologically confirmed that Recurrent or Metastatic Nasopharyngeal Carcinoma. 4. Patients must have received at least one standard platinum-based systemic chemotherapy regimen for the treatment of recurrent or metastatic NPC;Or the insensitivity or intolerance to platinum when the patient has previously received radical therapy; 5. Not suitable for local treatment (no radiotherapy or surgery); 6. Presence of at least one measurable target lesion for further evaluation according to RECIST criteria; 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2; 8. Screening laboratory values must meet the following criteria (within past 14 days): * neutrophils ≥1.5×109/L ; * platelets ≥100×109/L； * hemoglobin ≥ 10 g/dL; * total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1.5╳ULN; 9. Ability to follow the program; 10. Toxic side effects of any previous chemotherapy have returned to less than or equal to NCI CTCAE1 level or baseline; 11. Predicted survival \>3 months; 12. Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 6 months after the last dose of study drug. Exclusion Criteria: 1. The pathological type was neuroendocrine or small cell carcinoma; 2. Evidence with active CNS disease or previous brain metastases; 3. Prior received anti-tumor monoclonal antibodies or other investigational drugs within the first 4 weeks of enrollment;Previous treatment with other anti-PD-1 antibodies or other treatments targeting PD-1 / PD-L1. 4. Prior treatment with Surufatinib,or other antiangiogenic drugs were used ; 5. Patients were on immunosuppressive or systemic hormone therapy (doses greater than 10mg/day prednisone or other equivalent hormone) for immunosuppressive purposes and were still on it within 2 weeks prior to enrolment; 6. The patient has any active autoimmune disease or a history of autoimmune disease; 7. Have clinical cardiac symptoms or diseases that are not well controlled; 8. Patients with congenital or acquired immune deficiency; 9. Chemotherapy, targeted therapy and radiotherapy were received within 2 weeks before enrollment; 10. Patients who had a history of gastrointestinal perforation or had undergone major surgery 4 weeks before enrollment; 11. During the first 6 months of enrollment, there were arterial/venous thrombosis events, such as non-cardiovascular and cerebrovascular (including temporary ischemic attack), deep vein thrombosis (except for venous thrombosis caused by intravenous catheterization during pre-chemotherapy, which was determined by the investigators to be cured), and pulmonary embolism; 12. Patients with abnormal coagulation function (International normalized ratio (INR) \>1.5 or partially activated prothrombin time (APTT) \>1.5×ULN), bleeding tendency (such as active ulcer lesions in the stomach, occlusive blood in the stool (++), melenia and/or hematemesis and hemoptysis within 3 months) or lesions close to large vessels.The lesions involved in the skin or mucosal cavity are at risk of rupture; 13. Hypertension that cannot be controlled by medication; 14. Routine urine indicated more than 2+ urine protein or 24 hours urine protein \>150mg/L; 15. Calibration of QT interval \> 470MSEC;If the patient has an extended QT interval, but the investigator's study evaluates the prolonged period as due to a pacemaker (and no other cardiac abnormality), it is up to the investigator to determine whether the patient is eligible for the study; 16. Had other malignant tumors in the past 5 years (except for basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ that have been effectively controlled); 17. Known to be allergic to drug ingredients; 18. Patients at risk of massive bleeding in the nasopharynx or deep ulcers in the nasopharynx.